WO2020168143A1 - Substituted bicyclic compounds as farnesoid x receptor modulators - Google Patents

Substituted bicyclic compounds as farnesoid x receptor modulators Download PDF

Info

Publication number
WO2020168143A1
WO2020168143A1 PCT/US2020/018203 US2020018203W WO2020168143A1 WO 2020168143 A1 WO2020168143 A1 WO 2020168143A1 US 2020018203 W US2020018203 W US 2020018203W WO 2020168143 A1 WO2020168143 A1 WO 2020168143A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
bicyclo
phenyl
methyl
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/018203
Other languages
English (en)
French (fr)
Inventor
Dean A. Wacker
Susheel Jethanand NARA
Srinivas CHERUKU
Kandhasamy SARKUNAM
Firoz Ali JAIPURI
Soodamani THANGAVEL
Rishikesh Narayan
Subba Reddy BANDREDDY
Srinivas JOGI
Pavan Kalyan KATHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202080029369.9A priority Critical patent/CN113710656B/zh
Priority to EA202192276A priority patent/EA202192276A1/ru
Priority to SG11202108792WA priority patent/SG11202108792WA/en
Priority to EP20711418.2A priority patent/EP3924336A1/en
Priority to MX2021009694A priority patent/MX2021009694A/es
Priority to KR1020217029597A priority patent/KR102927636B1/ko
Priority to PE2021001326A priority patent/PE20211701A1/es
Priority to IL285246A priority patent/IL285246B2/en
Priority to JP2021547528A priority patent/JP7476216B2/ja
Priority to BR112021015689-5A priority patent/BR112021015689A2/pt
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to AU2020223316A priority patent/AU2020223316A1/en
Priority to CA3129492A priority patent/CA3129492A1/en
Publication of WO2020168143A1 publication Critical patent/WO2020168143A1/en
Priority to CONC2021/0010611A priority patent/CO2021010611A2/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates generally to compounds useful as farnesoid X receptor (FXR) modulators, pharmaceutical compositions comprising such compounds and to their use in therapy, especially in the treatment or prophylaxis of diseases, disorders, and conditions for which an FXR modulator is indicated.
  • FXR farnesoid X receptor
  • FXR or NR1H4 is a nuclear receptor that can activate the expression of specific target genes in a ligand-dependent manner.
  • FXR is expressed in the liver, throughout the gastrointestinal tract, colon, ovary, adrenal gland, kidney, and in the gall bladder and biliary tree in humans.
  • FXR forms a heterodimer with Retinoid X Receptor (RXR) and binds to specific response elements in target genes to regulate gene transcription (B. M. Forman et al., Cell 1995; 81 : 687; W. Seol et al., Mol. Endocrinol. 1995; 9: 72).
  • the FXR/RXR heterodimer typically binds to an inverted repeat of a consensus hexanucleotide sequence (AGGTCA) separated by a single nucleotide, i.e. an IR-1 sequence.
  • AGGTCA consensus hexanucleotide sequence
  • the relevant physiological ligands of FXR are bile acids including chenodeoxycholic acid and its taurine-conjugate (D. J. Parks et al., Science 1999; 284: 1365; M. Makishima et al., Science 1999; 284: 1362).
  • FXR activation regulates the expression of multiple genes that encode enzymes and
  • FXR is involved in paracrine and endocrine signaling by upregulating the expression of the cytokine Fibroblast Growth Factor 15 (rodents) or 19 (primates), which can also contribute to the regulation of bile acid concentrations (Holt et al., Genes Dev. 2003; 17: 1581; Inagaki et al., Cell Metab 2005; 2: 217). Therefore, FXR is considered to be a master regulator of bile acid homeostasis.
  • FXR agonists are for the treatment of diseases in which bile acids are dysregulated, including cholestatic diseases (e.g. primary biliary cirrhosis and primary sclerosing cholangitis) that can lead to fibrosis, cirrhosis, cholangiocarcinoma, hepatocellular carcinoma, liver failure, and death. While elevated bile acid
  • bile acids also affect the microflora and integrity of the small intestine. Obstruction of bile flow in humans or rodents causes proliferation of intestinal bacteria and mucosal injury, which can lead to bacterial translocation across the mucosal barrier and systemic infection (Berg, Trends Microbiol. 1995; 3: 149-154). Mice lacking FXR have increased ileal levels of bacteria and a compromised epithelial barrier, while activation of intestinal FXR plays an important role in preventing bacterial overgrowth and maintaining the integrity of the intestinal epithelium (Inagaki et ah, Proc Natl Acad Sci 2006; 103: 3920-3925).
  • FXR null mice spontaneously develop hepatocellular carcinoma, and this can be abrogated by selective re-activation of FXR in the intestine (Degirolamo et al., Hepatology 61 : 161- 170).
  • Pharmacological activation of FXR with a small molecule agonist or transgenic expression of FXR in the intestine can normalize bile acid concentrations, decrease cellular proliferation in hepatic bile ducts, and reduce inflammatory cell infiltration, necrotic area, and liver fibrosis in rodent models of cholestasis (Liu et al., J. Clin. Invest.
  • FXR agonists regulate the hepatic expression of hundreds of genes encoding proteins involved in cholesterol and lipid metabolism and transport, glucose homeostasis, inflammation, chemotaxis, and apoptosis among other pathways (Zhan et al., PLoS One 2014; 9: el05930; Ijssennagger et al., J Hepatol 2016; 64: 1158-1166).
  • FXR agonists have also been investigated in preclinical models of fibrosis, cancer, inflammatory diseases, and metabolic disorders, including dyslipidemia, obesity, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and metabolic syndrome (Crawley, Expert Opin. Ther. Patents 2010; 20: 1047-1057).
  • NAFLD nonalcoholic steatohepatitis
  • the risk factors for developing NAFLD include obesity, type 2 diabetes mellitus (T2DM), insulin resistance, hypertension, and dyslipidemia.
  • T2DM type 2 diabetes mellitus
  • the FXR agonist OCA statistically significantly improved insulin sensitivity and reduced body weight, showing beneficial effects on some of these risk factors (Mudaliar et al., Gastroenterology 2013; 145: 574- 582).
  • NASH is the most severe and progressive form of NAFLD and includes the histological findings of hepatic steatosis, inflammation, and ballooning degeneration with varying amounts of pericellular fibrosis (Sanyal et al., Hepatology 2015; 61 : 1392-1405).
  • HCC hepatocellular carcinoma
  • liver transplantation in the United States (Wong et al., Hepatology 2014; 59: 2188-2195).
  • the present invention provides novel compounds for treating a disease, disorder, or condition associated with farnesoid X receptor (FXR) activity in a patient in need thereof.
  • FXR farnesoid X receptor
  • the present invention provides compounds of Formula (I) as well as the subgenera and species thereof, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates thereof, which are useful as FXR modulators.
  • the present invention also provides processes and intermediates for making the compounds of the present invention.
  • the present invention also provides pharmaceutical
  • compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof.
  • the compounds of the invention may be used in therapy, either alone or in combination with one or more additional therapeutic agents.
  • the compounds of the invention may be used in the treatment of a disease, disorder, or condition associated with activity of famesoid X receptor (FXR) in a patient in need of such treatment by administering a therapeutically effective amount of the compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • the disease, disorder, or condition may be related to pathological fibrosis.
  • the compounds of the invention can be used alone, in combination with one or more compounds of the present invention, or in combination with one or more, e.g., one to two, other therapeutic agents.
  • the compounds of the invention may be used, either as a single agent or in combination with other agents, in the treatment of a disease, disorder, or condition selected from nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC), and primary biliary cirrhosis (PBC).
  • NASH nonalcoholic steatohepatitis
  • NAFLD non-alcoholic fatty liver disease
  • PSC primary sclerosing cholangitis
  • PBC primary biliary cirrhosis
  • IPF idiopathic pulmonary fibrosis
  • the compounds of the invention may be used for the manufacture of a
  • FIG. l shows the general reaction Scheme 12.
  • FIG.2 shows the general reaction Scheme 13.
  • FIG.3 shows the general reaction Scheme 15. DETAILED DESCRIPTION
  • the present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable salt and solvate forms thereof, according to Formula (I).
  • the present application also provides pharmaceutical compositions containing at least one compound according to Formula (I), or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof, and optionally at least one additional therapeutic agent.
  • the present application provides methods for treating a patient suffering from a FXR-modulated disease or disorder such as for example, biliary fibrosis, liver fibrosis, renal fibrosis, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steato-Hepatitis (NASH), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and pancreatic fibrosis, by administering to a patient in need of such treatment a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or a solvate thereof, and optionally in combination with at least one additional therapeutic agent.
  • a FXR-modulated disease or disorder such as for example, biliary fibrosis, liver fibrosis, renal fibrosis, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Stea
  • the first aspect of the present invention provides a compound of Formula (I):
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N
  • X 4 is CR 5d or N; provided that zero, 1, or 2 of X 1 , X 2 , X 3 , and X 4 are N;
  • Z 1 and Z 2 are independently CTE or O; provided that at least one of Z 1 and Z 2 is CTE; a is zero or 1;
  • b is zero, 1, or 2;
  • d is zero, 1, or 2; provided that Z 1 and Z 2 are each CH2 when a, b, and d are each zero;
  • Q is a cyclic group selected from 3- to 8-membered carbocyclyl, 6- to 10-membered aryl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 4 R 1 ;
  • each R 1 is independently hydrogen, halo, cyano, hydroxyl, oxo, Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 alkoxy, -NH2, -NH(CI- 6 alkyl), -N(CI- 6 alkyl)2, -C(0)(Ci- 6 alkyl), -C(0)(C 3-6 cycloalkyl), -NR x C(0)R y , -C(0)OR x , -C(0)NR w R w , -S(0) 2 (Ci- 6 alkyl), -S(0) 2 (C 3-6 cycloalkyl), -NR x S(0) 2 (Ci- 6 alkyl), -NR x S(0) 2 (C 3-6 cycloalkyl), -S(0) 2 NR Z R z , -P(0)R y R y , -(CH2) O-3 (C 3 -6 carbocyclyl), -
  • each R la is independently halo, hydroxyl, -NR W R W , oxo, cyano, Ci- 3 alkoxy, Ci- 3
  • each R lb is independently halo, oxo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), -N(C I-6 alkyl)2, or -NR X C(0)(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la ;
  • R 2 is:
  • each R 2a is independently halo, cyano, hydroxyl, oxo, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, -NR X R X , -C(0)(Ci- 6 alkyl), -C(0)(C 3-6 cycloalkyl), -NR x C(0)R y , -C(0)(Ci-6 alkyl), -C(0)0R x , -C(0)NR w R w , -S(0) 2 R y , -S(0) 2 (Ci- 3 fluoroalkyl), -NR X S(0) 2 (C I-3 alkyl), -NR x S(0) 2 (C 3-6 cycloalkyl), -S(0) 2 NR z R z , or -P(0)R y R y ; each R 2b is independently halo, cyano, hydroxyl, oxo, Ci- 6 alkyl, Ci- 6 al
  • R 3a and R 3b are independently hydrogen, Ci- 3 alkyl, Ci- 3 haloalkyl, or C 3-6 cycloalkyl, or R 3a and R 3b , taken together with the carbon atom to which they are attached, form a
  • A is:
  • each R 4a is independently halo, cyano, hydroxyl, -NH 2 , Ci- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci-6 alkoxy, -(CH 2 )O- 3 NH(CI-6 alkyl), -(CH 2 )O- 2 N(CI-6 alkyl) 2 ,
  • R 4b is Ci- 6 alkyl, -(CH2)o-3(C3-6 cycloalkyl), -(CH 2 )o- 3 (4- to 6-membered heterocyclyl), or -(CH2)o-3(phenyl), wherein each of said alkyl is substituted with zero to 6 R 4d and each of said cycloalkyl, heterocyclyl, and phenyl is substituted with zero to 3 R 4e ; each R 4C is independently hydrogen, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered
  • heterocyclyl phenyl, or 5- to 6-membered heteroaryl
  • each R 4d is independently halo, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, or C 1-3
  • each R 4e is independently halo, oxo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), or -N(C I-6 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 6 R 4d ;
  • each of R 5a , R 5b , R 5c , and R 5d is independently hydrogen, halo, hydroxy, cyano, Ci- 6 alkyl substituted with zero to 6 R 5e , Ci- 6 alkoxy substituted with zero to 6 R 5e , -C(0)OR x , -C(0)NR w R w , -S(0) 2 R y , -S(0) 2 NR Z R z , or phenyl substituted with zero to 3 R 5f ; each of R 5e is independently halo, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, or C 1-3 haloalkoxy;
  • each R 5f is independently halo, oxo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), or -N(C I-6 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 6 R 5e ;
  • each R v is independently hydrogen, Ci- 6 alkyl, or alternatively, two R v , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered bicyclic or spirocyclic ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S, wherein each ring can be substituted with zero to 6 R 2a ;
  • each R w is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl; or alternatively, two R w , taken together with the nitrogen atom to which they are attached, form a 4- to 7- membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;
  • each R x is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl
  • each R y is independently Ci- 6 alkyl or C3-6 cycloalkyl
  • each R z is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl; or alternatively, two R z , taken together with the nitrogen atom to which they are attached, form a 4- to 7- membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.
  • the second aspect of the present invention provides a compound of Formula (I):
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N
  • X 4 is CR 5d or N; provided that zero, 1, or 2 of X 1 , X 2 , X 3 , and X 4 are N;
  • Z 1 and Z 2 are independently CFh or O; provided that at least one of Z 1 and Z 2 is CFh; a is zero or 1;
  • b is zero, 1, or 2;
  • d is zero, 1, or 2; provided that Z 1 and Z 2 are each CFh when a, b, and d are each zero;
  • Q is a cyclic group selected from 3- to 8-membered carbocyclyl, 6- to 10-membered aryl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 4 R 1 ;
  • each R 1 is independently hydrogen, halo, cyano, hydroxyl, oxo, Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 alkoxy, -NFh, -NH(CI- 6 alkyl), -N(CI- 6 alkyl)2, -C(0)(Ci- 6 alkyl), -C(0)(C 3-6 cycloalkyl), -NR x C(0)R y , -C(0)0R x , -C(0)NR w R w , -S(0) 2 (Ci- 6 alkyl), -S(0) 2 (C 3-6 cycloalkyl), -NR x S(0) 2 (Ci- 6 alkyl), -NR x S(0) 2 (C 3-6 cycloalkyl), -S(0) 2 NR Z R z , -P(0)R y R y , -(CH2) O-3 (C 3 -6 carbocyclyl),
  • each of said alkyl, alkoxy, alkenyl, and alkynyl is substituted with zero to 4 R la and each of said cycloalkyl, heterocyclyl, and heteroaryl is substituted with zero to 4 R lb ;
  • each R la is independently halo, hydroxyl, -NR W R W , oxo, cyano, C 1-3 alkoxy, C 1-3 haloalkoxy, -C(0)OR x , -C(0)NR w R w , or -NR x C(0)R y ;
  • each R lb is independently halo, oxo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), -N(C I-6 alkyl)2, or -NR X C(0)(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la ;
  • R 2 is:
  • each R 2a is independently halo, cyano, hydroxyl, oxo, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, -NR X R X , -C(0)(Ci- 6 alkyl), -C(0)(C 3-6 cycloalkyl), -NR x C(0)R y , -C(0)(Ci-6 alkyl), -C(0)OR x , -C(0)NR w R w , -S(0) 2 R y , -S(0) 2 (Ci- 3 fluoroalkyl), -NR X S(0) 2 (CI-3 alkyl), -NR x S(0) 2 (C 3-6 cycloalkyl), -S(0) 2 NR z R z , or -P(0)R y R y ; each R 2b is independently halo, cyano, hydroxyl, oxo, Ci- 6 alkyl, Ci- 6 alkoxy
  • R 3a and R 3b are independently hydrogen, C 1-3 alkyl, C 1-3 haloalkyl, or C 3-6 cycloalkyl, or R 3a and R 3b , taken together with the carbon atom to which they are attached, form a C 3-6 cycloalkyl;
  • A is: (i) cyano
  • each R 4a is independently halo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 alkoxy, -(CH2)O-3NH(CI-6 alkyl), -(CH2)O-2N(CI-6 alkyl)2,
  • R 4b is Ci-6 alkyl, -(CH2)o-3(C3-6 cycloalkyl), or -( ⁇ 1 ⁇ 4)o-3(4- to 6-membered
  • heterocyclyl wherein each of said alkyl is substituted with zero to 6 R 4d and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R 4e ;
  • each R 4C is independently hydrogen, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered
  • heterocyclyl phenyl, or 5- to 6-membered heteroaryl
  • each R 4d is independently halo, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, or C 1-3
  • each R 4e is independently halo, oxo, cyano, hydroxyl, -NH2, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), or -N(C I-6 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 6 R 4d ;
  • each of R 5a , R 5b , R 5c , and R 5d is independently hydrogen, halo, hydroxy, cyano, Ci- 6 alkyl substituted with zero to 6 R 5e , Ci- 6 alkoxy substituted with zero to 6 R 5e , -C(0)0R x , -C(0)NR w R w , -S(0) 2 R y , -S(0) 2 NR Z R z , or phenyl substituted with zero to 3 R 5f ; each of R 5e is independently halo, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, or C 1-3 haloalkoxy;
  • each R 5f is independently halo, oxo, cyano, hydroxyl, -NFh, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), or -N(C I-6 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 6 R 5e ;
  • each R v is independently hydrogen, Ci- 6 alkyl, or alternatively, two R v , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered bicyclic or spirocyclic ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S, wherein each ring can be substituted with zero to 6 R 2a ;
  • each R w is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl; or alternatively, two R w , taken together with the nitrogen atom to which they are attached, form a 4- to 7- membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S;
  • each R x is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl
  • each R y is independently Ci- 6 alkyl or C3-6 cycloalkyl
  • each R z is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl; or alternatively, two R z , taken together with the nitrogen atom to which they are attached, form a 4- to 7- membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.
  • a compound of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof is provided, wherein X 1 is CR 5a ; X 2 is CR 5b ; X 3 is CR 5c ; X 4 is CR 5d .
  • R 5a , R 5b , R 5c , and R 5d are F, Cl, cyano, or -OCH3; and three of R 5a , R 5b , R 5c , and R 5d are hydrogen.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is N; X 2 is CR 5b ; X 3 is CR 5c ; and X 4 is CR 5d .
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is N; X 3 is CR 5c ; and X 4 is CR 5d .
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is CR 5b ; X 3 is N; and X 4 is CR 5d .
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is CR 5b ; X 3 is CR 5c ; and X 4 is N.
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is N; X 3 is CR 5c ; and X 4 is N.
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is N; X 2 is CR 5b ; X 3 is CR 5c ; and X 4 is N.
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is N; X 2 is N; X 3 is CR 5c ; and X 4 is CR 5d .
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is N; X 3 is N; and X 4 is CR 5d .
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is CR 5b ; X 3 is N; and X 4 is N.
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is CR 5b ; X 3 is CR 5c ; X 4 is CR 5d ; and Z 1 and Z 2 are each CFh.
  • Compounds of this embodiment have the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 is CR 5a ; X 2 is CR 5b ; X 3 is CR 5c ; X 4 is CR 5d ; Z 1 and Z 2 are each CFh; and a, b, and d are each 1.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: a is 1; b is 1 ; and d is 1.
  • Compounds of this embodiment have the structure:
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N; and X 4 is CR 5d or N; provided that zero or 1 of X 1 , X 2 , X 3 , and X 4 is N.
  • R 5a , R 5b , R 5c , and R 5d are selected from hydrogen and F, provided that zero or 1 of R 5a , R 5b , R 5c , and R 5d is F.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: a is 1; b is 1 ; d is 1; Z 1 is CFh; and Z 2 is CFh.
  • Compounds of this embodiment have the structure:
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N
  • X 4 is CR 5d or N; provided that zero or 1 of X 1 , X 2 , X 3 , and X 4 is N.
  • R 5a , R 5b , R 5c , and R 5d are selected from hydrogen and F, provided that zero or 1 of R 5a , R 5b , R 5c , and R 5d is F.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: a is 1; b is 1 ; d is 1 ; Z 1 is CFh; and Z 2 is O.
  • Compounds of this embodiment have the structure:
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N
  • X 4 is CR 5d or N; provided that zero or 1 of X 1 , X 2 , X 3 , and X 4 is N.
  • X 1 is CR 5a
  • X 2 is CR 5b
  • X 3 is CR 5c
  • X 4 is CR 5d .
  • R 5a , R 5b , R 5c , and R 5d are selected from hydrogen and F, provided that zero or 1 of R 5a , R 5b , R 5c , and R 5d is F.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: a is 1; b is 1 ; d is 1 ; Z 1 is O; and Z 2 is CH2.
  • Compounds of this embodiment have the structure:
  • X 1 is CR 5a or N
  • X 2 is CR 5b or N
  • X 3 is CR 5C or N; and X 4 is CR 5d or N; provided that zero or 1 of X 1 , X 2 , X 3 , and X 4 is N.
  • X 1 is CR 5a ;
  • X 2 is CR 5b ;
  • X 3 is CR 5c ;
  • X 4 is CR 5d .
  • R 5a , R 5b , R 5c , and R 5d are selected from hydrogen and F, provided that zero or 1 of R 5a , R 5b , R 5c , and R 5d is F.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a cyclic group selected from 3- to 8-membered carbocyclyl, phenyl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 3 R 1 ;
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 3- to 8- membered carbocyclyl substituted with zero to 4 R 1 .
  • Q is C3-6 cycloalkyl, spiro[2.3]hexanyl, spiro[2.4]heptanyl, spiro[3.3]heptanyl, spiro[3.3]heptenyl, spiro[3.4]octanyl, or oxaazaspiro[3.3]heptanyl, each substituted with zero to 4 R 1 .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 6- to 10- membered aryl substituted with zero to 4 R 1 . Included in this embodiment are
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 4- to 10- membered heterocyclyl substituted with zero to 4 R 1 . Included in this embodiment are compounds in which Q is a 4- to 6-membered heterocyclyl substituted with zero to 4 R 1 . Also included in this embodiment are compounds in which Q is azetidinyl, pyrrolidinyl, piperazinyl, piperidinyl, or morpholinyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5- to 10- membered heteroaryl substituted with zero to 4 R 1 . Included in this embodiment are compounds in which Q is a 5- to 6-membered heteroaryl substituted with zero to 4 R 1 .
  • Q is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl, indazolyl, indolinyl, quinolinyl, isoquinolinyl, [l,2,4]triazolo[l,5-a] pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, lH-pyrazolo[3,4-b]pyridinyl, 2,3- dihydrobenzo[d]oxazolyl, 7,8-dihydro-5H-pyrano[4,3-b]pyridinyl, benzo[d][l,3]dioxolyl, benzo[d]oxazolyl,
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein A is phenyl or a 5- or 10-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, wherein each of said phenyl and heteroaryl is substituted with zero to 3 R 4a .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein A is phenyl or a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, wherein each of said phenyl and heteroaryl is substituted with zero to 3 R 4a .
  • A is oxadiazolyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, pyrimidinyl, thiadiazolyl, or thiazolyl, each substituted with zero to 2 R 4a .
  • A is a 5- or 6- membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O, and S, wherein said heteroaryl is substituted with zero to 3 R 4a .
  • A is phenyl substituted with zero to 2 R 4a .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein A is:
  • A is -C(0)NH(cyclopropyl), -NHS(0) 2 CF 3 , -NHC(0)0CH(CH 3 ) 2 , -NHC(0)NHCH(CH 3 ) 2 , or -C(0)NHS(0) 2 (cyclopropyl).
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein A is:
  • A is: Also included in this embodiment are compounds in which A is -C(0)NH(cyclopropyl), -NHS(0)2CF3, -NHC(0)0CH(CH3)2, or
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 alkoxy, or -NR V R V , wherein each of said alkyl, alkenyl, alkynyl, and alkoxy is substituted with zero to 6 R 2a . Included in this embodiment are compounds in which R 2 is C1-4 alkyl, C1-5 alkoxy, or -NH(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a . Also included in this embodiment are compounds in which R 2 is -CH(CH3)2, -NHCH2CH3, or
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is C3-5 carbocyclyl, C 6-8 spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R 2b .
  • R 2 is C3-5 carbocyclyl, C 6-8 spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 2 R 2b .
  • R 2 is C3-5 cycloalkyl, azetidinyl, oxetanyl, pyrrolidinyl, and bicyclo[l. l.l]pentyl, each cyclic group substituted with zero to 2 substituents
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is
  • heterocyclyl -0(CFh)o- 2 (5- to 6-membered heteroaryl), or -0(CFh)o- 2 (phenyl), wherein each of said cycloalkyl, heterocyclyl, bicycloalkyl, spirobicyclyl, aryl, and heteroaryl is substituted with zero to 3 R 2b .
  • R 2 is -CH2(C3-5 cycloalkyl), -CH2(4- to 6-membered heterocyclyl), -NR x (CFh)o-2(C3-5 cycloalkyl), -NR x (CH 2 )o- 2 (4- to 6-membered heterocyclyl), -NR x (CH2)o-2(phenyl), -O(phenyl), or -O(pyridinyl), wherein each of said cycloalkyl, heterocyclyl, phenyl, and pyridinyl is substituted with zero to 3 R 2b . Also included in this embodiment are compounds in which R 2 is -NH(methyl cyclopropyl) or -NH(methoxyphenyl).
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3a and R 3b are independently hydrogen, C 1-3 alkyl, C 1-3 fluoroalkyl, or C 3-6 cycloalkyl, or R 3a and R 3b , taken together with the carbon atom to which they are attached, form a C 3-6 cycloalkyl. Included in this embodiment are compounds in which R 3a and R 3b are independently hydrogen, C 1-2 alkyl, C 1-2 fluoroalkyl, or C 3-6 cycloalkyl.
  • R 3a and R 3b are independently hydrogen, -CH 3 , or -CF 3 . Additionally, included in this embodiment are compounds in which one of R 3a and R 3b is hydrogen and the other of R 3a and R 3b is hydrogen or -CH 3 .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R la is independently F, Cl, hydroxyl, -NR W R W , oxo, cyano, C 1-3 alkoxy, C 1-3 fluoroalkoxy, or -C(0)OH. Included in this embodiment are compounds in which each R la is
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R lb is independently halo, oxo, cyano, hydroxyl, -NFh, Ci- 6 alkyl, Ci- 6 alkoxy, -NH(C I-6 alkyl), -N(C I-6 alkyl)2, or -NR X C(0)(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la .
  • each R lb is independently F, Cl, oxo, cyano, hydroxyl, -NFh, C 1-4 alkyl, C 1-4 alkoxy, -NH(C I-4 alkyl), -N(C I-4 alkyl)2, or -NR X C(0)(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la .
  • each R la is independently F, cyano, hydroxyl, or -OCH 3 .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R lb is independently F, Cl, Br, oxo, cyano, hydroxyl, -NFh, Ci- 6 alkyl, Ci- 4 alkoxy, -NH(C I-4 alkyl), -N(C I -4 alkyl)2, or -NR X C(0)(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la .
  • each R lb is independently F, Cl, oxo, cyano, hydroxyl, -NFh, Ci- 4 alkyl, Ci- 4 alkoxy, -NH(C I-4 alkyl), -N(C I-4 alkyl)2, or -NR X C(0)(C I-4 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 6 R la .
  • each R lb is independently F, Cl, cyano, hydroxyl, -CFb, or -OCFb.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R w is independently hydrogen, Ci- 4 alkyl, or C3-6 cycloalkyl; or alternatively, two R w , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R w is independently hydrogen, Ci- 6 alkyl, or C3-6 cycloalkyl. Included in this embodiment are compounds in which each R w is independently hydrogen, C 1-4 alkyl, or C3-6 cycloalkyl. Also included in this embodiment are compounds in which each R w is independently hydrogen or C 1-3 alkyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R x is independently hydrogen, C 1-4 alkyl, or C3-6 cycloalkyl. Included in this embodiment are compounds in which each R x is independently hydrogen or C 1-4 alkyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R y is independently C1-4 alkyl or C3-6 cycloalkyl. Included in this embodiment are compounds in which each R y is independently C 1-4 alkyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R z is independently hydrogen, Ci- 4 alkyl, or C 3-6 cycloalkyl; or alternatively, two R z , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered ring moiety containing zero to 2 additional heteroatoms independently selected from N, O, and S.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R z is independently hydrogen, Ci- 6 alkyl, or C 3-6 cycloalkyl. Included in this embodiment are compounds in which each R w is independently hydrogen, C 1-4 alkyl, or C 3-6 cycloalkyl. Also included in this embodiment are compounds in which each R z is independently hydrogen or C 1-3 alkyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2a is independently F, Cl, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, C 1-3 haloalkoxy, or -C(0)OH. Included in this embodiment are compounds in which each R 2a is
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2a is independently F, Cl, Br, cyano, hydroxyl, oxo, C 1-3 alkoxy, C 1-3 fluoroalkoxy, or -NR"R" . Included in this embodiment are compounds in which each R 2a is
  • each R 2a is independently F, cyano, hydroxyl, C 1-2 alkoxy, or -NR R
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2b is independently F, Cl, cyano, hydroxyl, C 1-4 alkyl, C 1-3 alkoxy, -NR X R X , -NR X C(0)0(C I-4 alkyl), -C(0)(Ci- 2 alkyl), or -S(0) 2 (Ci- 2 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2b is independently F, Cl, cyano, hydroxyl, C 1-3 alkyl, C 1-3 alkoxy, -NR X R X , -NR X C(0)0(C I-3 alkyl), -C(0)(Ci- 2 alkyl), or -S(0) 2 (Ci- 2 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a .
  • each R 2b is independently F, cyano, hydroxyl, C 1-3 alkyl, C 1-2 fluoroalkyl, C 1-3 hydroxyalkyl, Ci— 2 alkoxy, -NR X R X , -NR x C(0)0(Ci- 3 alkyl), -C(0)(Ci- 2 alkyl), -C(0)(Ci- 2 fluoroalkyl), or -S(0) 2 (Ci- 2 alkyl).
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 4a is independently F, Cl, Br, cyano, hydroxyl, -NH 2 , Ci- 6 alkyl, C 1-4 alkoxy,
  • each R 4a is independently F, Cl, cyano, hydroxyl, -NH 2 , C 1-4 alkyl, C 1-4 alkoxy, -(CH 2 ) O -3NH(C I -6 alkyl), -(CH 2 )O-3N(CI-6 alkyl) 2 , -(CH 2 )o-3(C3-6 cycloalkyl), or -(CH 2 )o-3(4- to 6- membered heterocyclyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 4d ; and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R 4e .
  • each R 4a is independently cyano, -CH3, -CH(CH 3 ) 2 , -C(CH 3 )3, -CHF 2 , -CF 3 , -C(CH 3 ) 2 F, -C(CH 3 ) 2 OH, -C(CH 3 ) 2 CN, -OCH3, -C(0)N(CH 3 ) 2 , -CH 2 (cyclopropyl), cyclopropyl, fluorocyclopropyl,
  • methylcyclopropyl cyanocyclopropyl, trifluoromethylcyclopropyl, difluorocyclopropyl, methyloxetanyl, tetrahydropyranyl, or fluorobicyclo[l. l.l]pentyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4b is C 1-4 alkyl, -(CH 2 )o-3(C3-6 cycloalkyl), -(CH 2 )o- 3 (4- to 6-membered heterocyclyl), or
  • each of said alkyl is substituted with zero to 6 R 4d and each of said cycloalkyl, heterocyclyl, and phenyl is substituted with zero to 3 R 4e .
  • R 4b is Ci-4 alkyl, -(CFh)o- 3 (C 3-6 cycloalkyl), or -(CH2)o-3(4- to 6- membered heterocyclyl), wherein each of said alkyl is substituted with zero to 4 R 4d and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R 4e .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 4c is independently hydrogen, Ci- 4 alkyl, or C 3-6 cycloalkyl. Included in this embodiment are compounds in which each R 4c is independently hydrogen, C 1-3 alkyl, or C 3-6 cycloalkyl. Also included in this embodiment are compounds in which each R 4c is independently hydrogen or -CH 3 .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 4d is independently F, Cl, hydroxyl, -NR X R X , cyano, C 1-3 alkoxy, or C 1-3 haloalkoxy. Included in this embodiment are compounds in which each R 4d is independently F, Cl, hydroxyl, -NR X R X , oxo, cyano, C 1-3 alkoxy, or C 1-3 fluoroalkoxy.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 4e is independently F, Cl, oxo, cyano, hydroxyl, -NFh, C 1-4 alkyl, C 1-4 alkoxy, -NH(C I-4 alkyl), or -N(C I -4 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 6 R 4d .
  • each R 4e is independently F, Cl, oxo, cyano, hydroxyl, -NFh, C 1-4 alkyl, C 1-4 alkoxy, or -NH(C I-6 alkyl), or -N(C I-6 alkyl)2, wherein each of said alkyl and alkoxy is substituted with zero to 4 R 4d .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is:
  • A is oxadiazolyl substituted with zero to 2 R 4a .
  • Q is phenyl substituted with 1 to 2 R 1 .
  • Q is oxadiazolyl substituted with zero to 2 R 1 .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein: Q is a cyclic group selected from 3- to 8-membered carbocyclyl, phenyl, 4- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl, wherein said cyclic group is substituted with zero to 3 R 1 ; each R 1 is independently F, Cl, Br, cyano, hydroxyl, oxo, -NR R , C 1-5 alkyl, C H alkoxy, -NR X (C I-4 alkyl), -NR x C(0)R y , -C(0)(Ci- 4 alkyl), -C(0)0R x , -C(0)NR w R w , -S(0) 2 (Ci- 4 alkyl), -S(0) 2 (Ci- 3-6 cycloalkyl), -NR x S(0) 2 (
  • R 2 is: (i) Ci- 4 alkyl, C 1-5 alkoxy, or -NR V R V , wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; (ii) C 3-5 carbocyclyl, C 6-8 spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R 2b ; or
  • A is: (i) cyano; (ii) phenyl or a 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, wherein each of said phenyl and heteroaryl is substituted with zero to 3 R 4a ; or
  • each R 4a is independently F, Cl, cyano, hydroxyl, -NFh, Ci- 4 alkyl, Ci- 4 alkoxy,
  • R 4b is Ci- 4 alkyl, -(CH 2 )o-3(C3-6 cycloalkyl), -(CH 2 )o- 3 (4- to 6- membered heterocyclyl), or -(CH 2 )o-3(phenyl), wherein each of said alkyl is substituted with zero to 6 R 4d and each of said cycloalkyl, heterocyclyl, and phenyl is substituted with zero to 3 R 4e ; each R 4c is independently hydrogen,
  • each R 1 is independently hydrogen, F, Cl, Br, cyano, hydroxyl, oxo, -NR X R X , C1-5 alkyl, C1-4 alkoxy, -NR X (C I-4 alkyl), -NR x C(0)R y , -C(0)(Ci- 4 alkyl), -C(0)OR x , -C(0)NR w R w , -S(0) 2 R y , -S(0) 2 (Ci-2 fluoroalkyl), -NR x S(0) 2 (Ci- 3 alkyl), -NR x S(0) 2 (C 3-6 cycloalkyl), -S(0) 2 NR Z R z , -P(0)R y R y , -(CH 2 )O-3(C3-6 carbocyclyl),
  • each R 4a is independently F, Cl, cyano, hydroxyl, -NFh, C1-4 alkyl, C1-4 alkoxy, -(CH2)O-3NH(CI-6 alkyl), -(CFh)o-3N(Ci-6 alkyl)2, -(CH2)o-3(C3-6 cycloalkyl), or -(CFh)o- 3 (4- to 6-membered heterocyclyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 4d ; and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R 4e ; R 4b is C1-4 alkyl,
  • each of said alkyl is substituted with zero to 4 R 4d and each of said cycloalkyl and heterocyclyl is substituted with zero to 3 R 4e ;
  • each R 4c is independently hydrogen, C1-3 alkyl, or C3-6 cycloalkyl;
  • each R 4d is independently F, Cl, hydroxyl, -NR3 ⁇ 4 X , oxo, cyano, C1-3 alkoxy, or Ci- 3 fluoroalkoxy;
  • each R 4e is independently F, Cl, oxo, cyano, hydroxyl, -NFh, C1-4 alkyl, C1-4 alkoxy, or -NH(C I-6 alkyl), or -N(C I-6 alkyl )2, wherein each of said alkyl and alkoxy is substituted with zero to 4 R 4d ; and each of R 5a
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 is CR 5a ; X 2 is CR 5b or N; X 3 is CR 5c or N; X 4 is CR 5d or N; provided that zero or 1 of X 2 , X 3 , and X 4 is N; Z 1 and Z 2 are independently CFh or O; provided that at least one of Z 1 and Z 2 is CFh; a is 1; b is 1; d is 1; Q is a cyclic group selected from cyclopropyl,
  • each R 1 is independently hydrogen, F, Cl, Br, cyano, hydroxyl, oxo, Ci- 4 alkyl, Ci- 2 fluoroalkyl, -CH 2 C1, Ci- 4 hydroxyalkyl, -CH 2 OCH 3 , Ci- 3 alkoxy, Ci- 2 fluoroalkoxy, -OC(CH 3 ) 2 CN, -C(0)0CH 2 CH 3 , -O(cyclopropyl),
  • acetamidocyclopropyl cyanocyclopropyl, difluorocyclopropyl, hydroxycyclopropyl, methoxycyclopropyl, cyclohexenyl, dihydropyranyl, oxetanyl, methyloxetanyl, tetrahydropyranyl, pyridinyl, or fluorobicyclo[l . l .
  • R 2 is: (i) Ci- 4 alkyl, Ci- 4 alkoxy, or -NH(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; (ii) C 3-5 carbocyclyl, C 6-8 spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R 2b ; or (iii) -CH 2 (C 3-5 cycloalkyl), -CH 2 (4- to 6-membered heterocyclyl),
  • each R 2a is independently F, cyano, hydroxyl, Ci- 2 alkoxy, or -NR R ; each R 2b is independently F, cyano, hydroxyl, Ci- 3 alkyl, Ci- 2 fluoroalkyl, Ci- 3 hydroxyalkyl, Ci- 2 alkoxy, -NR X R X , -NR X C(0)0(C I-3 alkyl), -C(0)(Ci- 2 alkyl), -C(0)(Ci- 2 fluoroalkyl), or -S(0) 2 (Ci- 2 alkyl); one of R 3a and R 3b is hydrogen and the other of R 3a and R 3b is hydrogen or -CH
  • R 5a , R 5b , R 5c , and R 5d is hydrogen.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 is CR 5a ; X 2 is CR 5b or N; X 3 is CR 5c or N; X 4 is CR 5d or N; provided that zero, 1, or 2 of X 2 , X 3 , and X 4 is N;
  • Z 1 and Z 2 are independently CH 2 or O; provided that at least one of Z 1 and Z 2 is CH 2 ; a is 1; b is 1; d is 1; Q is a cyclic group selected from cyclopropyl, spiro[3.3]heptenyl, bicyclo[2.2.2]octanyl, phenyl, azetidinyl, morpholinyl, oxaazaspiro[3.3]heptanyl, piperazinyl, piperidinyl, [l,2,4]triazolo[l,5-a] pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, lH-pyrazolo[3,4-b] pyridinyl, 2,3-dihydrobenzo[d]oxazolyl, 7,8-dihydro-5H-pyrano[4,3- b] pyridinyl, benzo[d][l,
  • Ci- 4 alkyl Ci- 2 fluoroalkyl, -CH 2 C1, Ci- 4 hydroxyalkyl, -C(CH ) 2 CN, -CH(OH)CHF 2 , -CH 2 OCH , C I-4 alkoxy, Ci- 2 fluoroalkoxy, -OCF 2 Cl, -OC(CH ) 2 CN, -C(CH ) 2 OCHF 2 , -0C(CH ) 2 C(0)NH 2 , -C(0)OH, -C(0)0(C I-2 alkyl), -C(0)NH 2 , -O(cyclopropyl), -CH 2 (cyclopropyl), -CH 2 (oxetanyl), -NHC(0)CH 3 , -NHS(0) 2 CH , -NHS(0) 2 CH(CH ) 2 , -NHS(0) 2 CF , -NHS(0) 2 (cyclopropyl), -NHC(0)CH 3 , -NHS(0)
  • -S(0) 2 CH 3 -S(0) 2 (cyclopropyl), -S(0) 2 NH 2 , cyclopropyl, acetamidocyclopropyl, cyanocyclopropyl, difluorocyclobutyl, hydroxycyclopropyl, methoxycyclopropyl, cyclohexenyl, dihydropyranyl, oxetanyl, methyloxetanyl, tetrahydropyranyl,
  • R 2 is: (i) Ci- 4 alkyl, C1-5 alkoxy, or -NH(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; (ii) C 3-5 carbocyclyl, C 6-8 spirobicyclyl, or 4- to 5-membered heterocyclyl, wherein each of said carbocyclyl, spirobicyclyl, and heterocyclyl is substituted with zero to 3 R 2b ; or (iii) -CFh(C3-5 cycloalkyl), -CFh(4- to 6-membered heterocyclyl),
  • each of said cycloalkyl, spirobicyclyl, heterocyclyl, phenyl, and pyridinyl is substituted with zero to 3 R 2b ;
  • each R 2a is independently F, cyano, hydroxyl, Ci— 2 alkoxy, or -NR3 ⁇ 4 X ;
  • each R 2b is independently F, cyano, hydroxyl, C1-3 alkyl, C1-2 fluoroalkyl, C1-3 hydroxyalkyl, C1-2 alkoxy, C1.2 fluoroalkoxy, -NR3 ⁇ 4
  • R 3a and R 3b are hydrogen and the other of R 3a and R 3b is hydrogen or -CFb;
  • A is: (i) pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, phenyl, pyridinyl, or pyrimidinyl, each substituted with zero to 2 R 4a ; or (ii) -C(0)NH(cyclopropyl),
  • each R 4a is independently cyano, -CH3, -CH(CH3)2, -C(CH 3 )3, -CHF2, -CPs, -CF2CH3, -C(CH 3 ) 2 F, -C(CH 3 ) 2 OH, -C(CH 3 ) 2 CN, -0CH3, -C(0)N(CH3)2, -CH2(cyclopropyl), cyclopropyl, fluorocyclopropyl, methylcyclopropyl, cyanocyclopropyl, trifluoromethylcyclopropyl, di fluorocyclopropyl, methyloxetanyl, tetrahydropyranyl, or fluorobicyclo[l . l . l]pentyl; and each of R 5a , R 5b , R 5c , and R 5d is hydrogen.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein
  • R 2 is -CH(CH ) 2 , -NHCH 2 CH , -NHCH 2 C(CH ) , -NH(methyl cyclopropyl),
  • each R 1 is independently C1-4 alkyl, -CHF 2 , -CF 3 , -CH 2 CF 3 , -CF 2 CH 3 , -CH 2 CHF 2 , -CH 2 C1, -C(CH ) 2 OH, -CH 2 OCH , -C(CH ) 2 OCH , -OCH , -OCH 2 CH , -C(0)OCH , -C(0)0CH 2 CH , -CH 2 (cy cl opropyl ), -S(0) 2 CH , -S(0) 2 (cyclopropyl), oxo, difluorocyclobutyl, fluorobicyclo[l . l .
  • R 3a is hydrogen or -CH 3
  • R 3b is hydrogen.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein X 1 is CH; X 2 is CH; X 3 is CH; X 4 is CH; Z 1 is CH 2 ; Z 2 is CH 2 ; a is 1; b is 1; d is 1; A is oxadiazolyl substituted with one R 4a ; R 2 is cyclobutyl substituted with zero to two R 2b ; and each R 2b is independently F, hydroxyl, cyano, -CHF 2 , -CF 3 , -C(CH 3 ) 2 OH, -OCH 3 , or -OCH 2 CH 3 .
  • Q is benzo[d]thiazolyl, imidazolyl, isoxazolyl, oxazolyl, phenyl, pyrazolyl, pyridinyl, or pyrimidinyl, each substituted with zero to 2 R 1 . Also included in this embodiment are compounds in which Q is
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is Ci- 6 alkoxy substituted with zero to 6 R 2a . Included in this embodiment are compounds in which R 2 is C 2-4 alkoxy substituted with zero to 3 R 2a . Also included in this embodiment are compounds in which R 2 is -OCH2CH3, -OCH(CH3)2, -OCH2CH(CH3)2,
  • R 2 is -OC(CH 3 ) 2 CN and -OC(CH 3 ) 2 CF 3 ;
  • A is oxadiazolyl substituted with zero to 2 R 4a ; and
  • Q is phenyl, oxazolyl, or oxadiazolyl substituted with zero to 2 R lb .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2 is C 2-4 alkoxy substituted with zero to 3 R 2a .
  • R 2 is -O CFb ⁇ CN and -OC(CH 3 ) 2 CF 3 .
  • A is oxadiazolyl substituted with zero to 2 R 4a ; and Q is phenyl, oxazolyl, or oxadiazolyl substituted with zero to 2 R lb .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2b is F, cyano, or -0(03 ⁇ 4) 2 0H.
  • R 5c CR 5c ;
  • X 4 is CR 5d ; and one of R 5a , R 5b , R 5c , and R 5d is hydrogen, F, Cl, cyano, or -OCH 3 , and the other three of R 5a , R 5b , R 5c , and R 5d are each hydrogen.
  • Z 1 is CFh and Z 2 is CFh.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2b is F, cyano, or -0(03 ⁇ 4) 2 0H. Also included in this embodiment are compounds in which one of R 5c and R 5d is hydrogen, F, Cl, cyano, or -OCH 3 , and the other R 5c and R 5d is hydrogen. Additionally, included in this embodiment are compounds in which R 2b is F; R 5c is hydrogen; and R 5d is hydrogen.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 4a is -0H(O3 ⁇ 4) 2 , -CFfcF, -CF3, -CF2CH3, cyclopropyl, fluorocyclopropyl, or methylcyclopropyl.
  • Q is phenyl or oxadiazolyl substituted with 1 to 2 R 1 .
  • Q is phenyl substituted with -C(CH ) 2 OH, -C(CH 3 ) 2 OCHF 2 , -OCH(CH ) 2 , or -OC(CH ) 2 CN, or cyanocyclopropyl.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 5c and R 5d is hydrogen and the other of R 5c and R 5d is hydrogen or F
  • one R 2b is hydroxyl and the other R 2b is -CH3, -CH2CH3, or -CF3
  • R 1 is -0(03 ⁇ 4) 2 0H, -C(CH3)20CHF2, -OCH(CH3)2, -OC(CH3)2CN, or cyanocyclopropyl
  • R 4a is -CF2CH3, -CH(CH ) 2 , -C(CH ) 2 F, cyclopropyl, or fluorocyclopropyl.
  • Included in this embodiment are compound in which one R 2b is hydroxyl and the other R 2b is -CH3 or -CH2CH3.
  • compounds in which one R 2b is hydroxyl and the other R 2b is -CF3.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • Q is phenyl substituted with R 4a .
  • Q is phenyl
  • A is oxadiazolyl substituted with R 4a ;
  • R 2 is: (i) C 1-4 alkyl, C 1-5 alkoxy, or -NH(C I-6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; or (ii) C 3-6 cycloalkyl substituted with zero to 3 R 2b .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2 is: (i) C 1-5 alkoxy or -NH(Ci- 6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; or (ii) cyclobutyl substituted with 1 to 3 R 2b .
  • R 4a is C2-3 alkyl substituted with 1 to 6 R 4d ; each R 4d is F; R 1 is C2-3 alkyl substituted with one R la ; and R la is hydroxyl.
  • R 4a is -CF3 or -C(CH3)2F.
  • R 1 is -0(03 ⁇ 4) 2 0H.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 4a is cyano, -CH3, -0H(O3 ⁇ 4) 2 , -C(CH 3 )3, -CHF2, -CF 3 , -C(CH 3 ) 2 F, -C(CH 3 ) 2 OH, -C(CH 3 ) 2 CN, -0CH3,
  • each R 1 is independently hydrogen, F, oxo, C1-3 alkyl, -CHF2, -C(CH ) 2 OH, -CH2OCH3, Ci— 3 alkoxy, -OCHF2, -OC(CH ) 2 CN, -O(cyclopropyl), -CH2(cyclopropyl), -NHS(0) 2 CH 3 , cyclopropyl, cyanocyclopropyl, dihydropyranyl, or tetrahydropyranyl .
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 4a is C 1-3 alkyl substituted with zero to 6 R 4d ; each R 4d is F; R 1 is C 1-3 alkyl substituted with zero to 2 R la ; and each R la is hydroxyl.
  • R 4a is C 2-3 alkyl substituted with 1 to 6 R 4d ; each R 4d is F; R 1 is C 2-3 alkyl substituted with one R la ; and R la is hydroxyl.
  • R 4a is -CF 3 or -C(CH 3 ) 2 F.
  • R 1 is -0(03 ⁇ 4) 2 0H.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2 is -NH(C I-6 alkyl), wherein said alkyl is substituted with zero to 4 R 2a .
  • R 2 is -NH(C2-4 alkyl), wherein said alkyl is substituted with zero to 2 R 2a . Also included in this embodiment are compounds in which R 2 is -NH(CH 2 CH ), -NH(CH(CH )2), -NH(CH 2 CH(CH 3 ) 2 ), or
  • R 2 is -NH(CH 2 CH ), -NH(CH(CH )2), -NH(CH 2 CH(CH 3 ) 2 ), or -NH(C(CH ) 3 ); and R 1 is C(CH 3 ) 2 OH.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2b is hydroxyl, -CH 3 , or -CF 3.
  • X 1 is CR 5a ;
  • X 2 is CR 5b ;
  • X 3 is CR 5c ;
  • X 4 is CR 5d ;
  • one of R 5a , R 5b , R 5c , and R 5d is hydrogen, F, Cl, cyano, or -OCH 3 , and the other three of R 5a , R 5b , R 5c , and R 5d are each hydrogen; and
  • Z 1 is CFh and Z 2 is CH 2.
  • One embodiment provides a compound of Formula (I) or a pharmaceutically acceptable salt, wherein said compound is:
  • One embodiment provides a compound of Formula (I) or a pharmaceutically acceptable salt, wherein said compound is:
  • One embodiment provides a compound of Formula (I) or a pharmaceutically acceptable salt, wherein said compound is:
  • One embodiment provides a compound of Formula (I) or a pharmaceutically acceptable salt, wherein said compound is:
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • Q is phenyl substituted with R 4a .
  • Q is phenyl; A is oxadiazolyl or pyridinyl substituted with R 4a ; and R 2 is: (i) C1-4 alkyl, C1-5 alkoxy, or -NH(CI- 6 alkyl), wherein each of said alkyl and alkoxy is substituted with zero to 4 R 2a ; or (ii) C3-5 cycloalkyl substituted with zero to 3 R 2b .
  • A is oxadiazolyl or pyridinyl substituted with -CF2CH3.
  • One embodiment provides a compound of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the structure:
  • R 2 is C 1-5 alkoxy, wherein said alkoxy is substituted with zero to 4 R 2a .
  • R 1 is - CFb ⁇ OH.
  • A is oxadiazolyl or pyridinyl, each substituted with -CF 2 CH 3 ;
  • R 1 is -C(CH 3 ) 2 OH; and
  • R 2 is -OC(CH 3 ) 2 CF 3.
  • the present invention provides a compound or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is:
  • neopentyl ((4-(5-(l, l-difluoroethyl)-l,2,4-oxadiazol-3-yl) bicyclo [2.2.2] octan-l-yl) methyl)(5-fluoro-4-(4-(2-hydroxypropan-2-yl) phenyl) pyridin-2-yl)carbamate (619);

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/US2020/018203 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators Ceased WO2020168143A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2021547528A JP7476216B2 (ja) 2019-02-15 2020-02-14 ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
SG11202108792WA SG11202108792WA (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators
EP20711418.2A EP3924336A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators
MX2021009694A MX2021009694A (es) 2019-02-15 2020-02-14 Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x.
KR1020217029597A KR102927636B1 (ko) 2019-02-15 2020-02-14 파르네소이드 x 수용체 조정제로서의 치환된 비시클릭 화합물
PE2021001326A PE20211701A1 (es) 2019-02-15 2020-02-14 Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x
IL285246A IL285246B2 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators
CN202080029369.9A CN113710656B (zh) 2019-02-15 2020-02-14 作为法尼醇x受体调节剂的经取代的双环化合物
EA202192276A EA202192276A1 (ru) 2019-02-15 2020-02-14 Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
BR112021015689-5A BR112021015689A2 (pt) 2019-02-15 2020-02-14 Compostos bicíclicos substituídos como moduladores de receptor de farnesoide x
AU2020223316A AU2020223316A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid X receptor modulators
CA3129492A CA3129492A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators
CONC2021/0010611A CO2021010611A2 (es) 2019-02-15 2021-08-12 Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806066P 2019-02-15 2019-02-15
US62/806,066 2019-02-15

Publications (1)

Publication Number Publication Date
WO2020168143A1 true WO2020168143A1 (en) 2020-08-20

Family

ID=69811921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/018203 Ceased WO2020168143A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Country Status (18)

Country Link
US (2) US11254663B2 (https=)
EP (1) EP3924336A1 (https=)
JP (1) JP7476216B2 (https=)
KR (1) KR102927636B1 (https=)
CN (1) CN113710656B (https=)
AR (1) AR118050A1 (https=)
AU (1) AU2020223316A1 (https=)
BR (1) BR112021015689A2 (https=)
CA (1) CA3129492A1 (https=)
CL (1) CL2021002093A1 (https=)
CO (1) CO2021010611A2 (https=)
EA (1) EA202192276A1 (https=)
IL (1) IL285246B2 (https=)
MX (1) MX2021009694A (https=)
PE (1) PE20211701A1 (https=)
SG (1) SG11202108792WA (https=)
TW (1) TWI808305B (https=)
WO (1) WO2020168143A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022152773A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Method for treating chronic kidney diseases
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2025012422A1 (en) * 2023-07-13 2025-01-16 Enyo Pharma L-arginine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
WO2025012038A1 (en) * 2023-07-13 2025-01-16 Enyo Pharma L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7465883B2 (ja) * 2019-02-15 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
AU2023261809A1 (en) * 2022-04-29 2024-12-05 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
CN115057996B (zh) * 2022-06-24 2023-06-02 河南工程学院 4CzIPN型多孔有机聚合物的制备方法及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074495A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Hppars activators
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2014071247A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2015005901A1 (en) 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015195880A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors
WO2016039734A1 (en) 2014-09-10 2016-03-17 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
WO2018170166A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013101A1 (fr) 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro
WO1998017276A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2004046162A2 (en) 2002-11-14 2004-06-03 The Scripps Research Institute Non-steroidal fxr agonists
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
WO2007076260A2 (en) 2005-12-19 2007-07-05 Smithkline Beecham Corporation Farnesoid x receptor agonists
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2108017A2 (en) 2007-01-30 2009-10-14 Biogen Idec MA, Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
US20110230493A1 (en) 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
EP2454243A2 (en) 2009-07-15 2012-05-23 Merck Serono SA Tetrazole derivatives
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
EP2655368A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IN2014DN09346A (https=) 2012-06-13 2015-07-17 Hoffmann La Roche
EP2903985A1 (en) 2012-10-03 2015-08-12 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2015172747A1 (en) 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
MX2017008057A (es) 2014-12-18 2017-09-28 Novartis Ag Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
US10703712B2 (en) * 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2017049177A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
ES2862194T3 (es) 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
WO2018170165A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170167A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20200131129A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
EP3917516A4 (en) * 2019-01-28 2022-10-12 Flatley Discovery Lab, LLC COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
CN113727973B (zh) * 2019-02-15 2025-08-29 百时美施贵宝公司 可用作类法尼醇x受体调节剂的取代酰胺化合物
AU2020222515B2 (en) 2019-02-15 2025-10-09 Nutrien Ag Solutions (Canada) Inc. The use of protoporphyrin IX derivatives to improve the health of plants
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074495A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Hppars activators
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2014071247A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
WO2014113485A1 (en) 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2015005901A1 (en) 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015195880A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors
WO2016039734A1 (en) 2014-09-10 2016-03-17 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
WO2018170166A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018170182A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, pages: 113 - 191
"Design of Prod rugs", 1985, ELSEVIER
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY
ACS MED. CHEM. LETT., vol. 5, 2014, pages 609 - 614
ARMIN DE MEIJEREFRANÇOIS DIEDERICH: "Metal-Catalyzed Cross-Coupling Reactions", vol. 2, 2004, WILEY-VCH
B. M. FORMAN ET AL., CELL, vol. 81, 1995, pages 687
BERG, TRENDS MICROBIOL., vol. 3, 1995, pages 149 - 154
BERNARD TESTAJOACHIM M. MAYER: "Hydrolysis in Drug and Prodrug Metabolism", 2003, WILEY-VCH
BIOORG. & MED. CHEM. LETT., vol. 27, 2017, pages 2192 - 2196
BOREN, B. C. ET AL., J. AM. CHEM. SOC., vol. 130, 2008, pages 8923 - 8930
BROSTROM, J. ET AL., J. MED. CHEM., vol. 55, 2012, pages 1817 - 1830
CAMILLE G. WERMUTH ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
CHARETTE, A. B. ET AL., ORG. LETT., vol. 17, 2015, pages 1184 - 1187
CHEDEKEL, M.R. ET AL., SYNTH. COMMUN., vol. 10, 1980, pages 167 - 173
CRAWLEY, EXPERT OPIN. THER. PATENTS, vol. 20, 2010, pages 1047 - 1057
DEGIROLAMO ET AL., HEPATOLOGY, vol. 61, 2015, pages 1392 - 1405
DOUGLASS, T. ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 7488 - 7494
DUNCTON, M. A., J. MED. CHEM. COMMUN., vol. 2, 2011, pages 1135 - 1161
FRANCE, S. ET AL., ORG. LETT., vol. 18, 2016, pages 4218 - 4221
GRAHAM, T. H., ORG. LETT., vol. 12, 2010, pages 3614 - 3617
HOLT ET AL., GENES DEV., vol. 17, 2003, pages 1581
IJSSENNAGGER ET AL., J HEPATOL, vol. 64, 2016, pages 1158 - 1166
INAGAKI ET AL., CELL METAB, vol. 2, 2005, pages 217
INAGAKI ET AL., PROC NATL ACAD SCI, vol. 103, 2006, pages 3920 - 3925
LING-BO, QU ET AL., ORG. BIOMOL. CHEM., vol. 13, 2015, pages 2750 - 2755
LIU ET AL., J. CLIN. INVEST., vol. 112, 2003, pages 1678 - 1687
M. MAKISHIMA ET AL., SCIENCE, vol. 284, 1999, pages 1362
MODICA ET AL., GASTROENTEROLOGY, vol. 142, 2012, pages 355 - 365
MUDALIAR ET AL., GASTROENTEROLOGY, vol. 145, 2013, pages 574 - 582
NEUSCHWANDER-TETRI ET AL., LANCET, vol. 385, 2015, pages 956 - 965
ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 13, 2015, pages 11597 - 11601
PASCAL, R. ET AL., EUR. J. ORG. CHEM., vol. 22, 2000, pages 3755 - 3761
RAUTIO, J. ET AL., NATURE REVIEW DRUG DISCOVERY, vol. 17, 2018, pages 559 - 587
SHIOIRI, T. ET AL., J. AM. CHEM. SOC., vol. 94, 1972, pages 6203 - 6205
SINGH, S. B. ET AL., ACSMED, CHEM. LETT., vol. 5, 2014, pages 609 - 614
SINGH, S. B. ET AL., ACSMED. CHEM. LETT., vol. 5, 2014, pages 609 - 614
STABILE, P. ET AL., TETRAHEDRON LETT., vol. 51, 2010, pages 4801 - 4805
TORRIYAMA, F. ET AL., J. AM. CHEM. SOC., vol. 138, 2016, pages 11132 - 11135
VARMA, R. S. ET AL., J. HETEROCYCLIC CHEM., vol. 35, 1998, pages 1533
VERNON ET AL., ALIMENT PHARMACOL THER, vol. 34, 2011, pages 274 - 285
W. SEOL ET AL., MOL. ENDOCRINOL., vol. 9, 1995, pages 72
WLOCHAL, J. ET AL., ORG. LETT., vol. 16, 2014, pages 4094 - 4097
WONG ET AL., HEPATOLOGY, vol. 59, 2014, pages 2188 - 2195
WRIGHT, S. W., J. MED. CHEM., vol. 45, 2002, pages 3865 - 3877
WUTSGREENE: "Greene's Protective Groups in Organic Synthesis", 2007, WILEY AND SONS
ZHAN ET AL., PLOS ONE, vol. 9, 2014, pages e105930

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
WO2022152770A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022152773A1 (en) 2021-01-14 2022-07-21 Enyo Pharma Method for treating chronic kidney diseases
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2025012422A1 (en) * 2023-07-13 2025-01-16 Enyo Pharma L-arginine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof
WO2025012038A1 (en) * 2023-07-13 2025-01-16 Enyo Pharma L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

Also Published As

Publication number Publication date
US11254663B2 (en) 2022-02-22
US11713312B2 (en) 2023-08-01
TWI808305B (zh) 2023-07-11
IL285246B1 (en) 2024-05-01
CO2021010611A2 (es) 2021-08-30
AU2020223316A1 (en) 2021-10-07
CA3129492A1 (en) 2020-08-20
BR112021015689A2 (pt) 2021-10-26
EP3924336A1 (en) 2021-12-22
IL285246A (en) 2021-09-30
CN113710656B (zh) 2026-04-17
SG11202108792WA (en) 2021-09-29
IL285246B2 (en) 2024-09-01
KR102927636B1 (ko) 2026-02-12
JP7476216B2 (ja) 2024-04-30
AR118050A1 (es) 2021-09-15
TW202045498A (zh) 2020-12-16
JP2022519770A (ja) 2022-03-24
EA202192276A1 (ru) 2021-11-26
KR20210127220A (ko) 2021-10-21
US20210261535A1 (en) 2021-08-26
PE20211701A1 (es) 2021-09-01
CL2021002093A1 (es) 2022-02-18
US20220135550A1 (en) 2022-05-05
MX2021009694A (es) 2021-09-10
CN113710656A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
US11713312B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
WO2019089667A1 (en) Bridged bicyclic compounds as farnesoid x receptor modulators
JP2015533157A (ja) ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
WO2020168148A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US12227496B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
WO2020168152A2 (en) Substituted amide compounds useful as farnesoid x receptor modulators
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20711418

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 285246

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3129492

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2021/0010611

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2021547528

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021015689

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: NC2021/0010611

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20217029597

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020711418

Country of ref document: EP

Effective date: 20210915

ENP Entry into the national phase

Ref document number: 2020223316

Country of ref document: AU

Date of ref document: 20200214

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112021015689

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210810

WWW Wipo information: withdrawn in national office

Ref document number: 001326-2021

Country of ref document: PE